About Chiesi Group
Chiesi Farmaceutici S.p.A. (Chiesi Group) is an Italian international pharmaceutical group based on research, developing and marketing innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. Chiesi Group is committed to improving people's quality of life and actively fulfilling its responsibilities to society and the environment.
As Chiesi's entities in Italy, the United States, France, and Colombia have become benefit corporations, Chiesi Group's commitment to creating shared value for society is legally binding and becomes a core consideration in corporate decision-making. Since 2019, Chiesi Group has been a B Corp certified pharmaceutical group, and as a member of the global B Corp community, the group continuously strives for sustainable development under rigorous standards. Chiesi Group aims to achieve 'net zero' targets by the end of 2035.
Chiesi Group is headquartered in Parma, Italy, with a 90-year history in the pharmaceutical industry, operating in 31 countries and regions worldwide, and employing over 7,500 people globally. Chiesi Group's R&D headquarters is in Parma, Italy, and it has six major R&D centers in France, the United States, Canada, China, the United Kingdom, and Sweden.
About Chiesi China
Thanks to China's reform and opening-up policy, Chiesi entered China through partners in 2001, and established its China headquarters in Shanghai in 2008, operating to date. More than 10% of Chiesi's global employees are from China, fully reflecting the group's emphasis on the Chinese market. In 2021, Chiesi also established a trading company in the Shanghai Waigaoqiao Free Trade Zone to respond more quickly to local needs.
Currently, Chiesi in China provides respiratory health and specialty treatment solutions covering the full lifecycle from newborns to the elderly, serving millions of patients and families, helping them improve quality of life and achieve smooth breathing. Chiesi is also accelerating the expansion of its rare disease business in China to benefit Chinese patients with rare diseases as soon as possible.
Continuing Chiesi Group's sustainable development philosophy, Chiesi China is also committed to leveraging the power of business for good, striving to create a positive impact on the local environment and communities while conducting business operations. In 2022, it launched the 'Chiesi China Marco Polo Program', aimed at accelerating the introduction of innovative drugs, promoting academic exchanges between China and Italy, and China and Europe, driving the implementation of health equity strategies in China, continuously improving medical accessibility and affordability, and deepening local partnerships. In 2025, the Marco Polo Program was upgraded to version 3.0, further expanding the local network.
We look forward to your joining!
For more information, please refer to the official WeChat public account: Chiesi Medical
What does Kaisy Medical Consulting (Shanghai) Co., Ltd. require? Who is Kaisy Medical hiring? Kaisy Medical recruitment: 销售类占比最多占85.1%，其次是医疗卫生/美容保健类占24.1%. What education can get in at Kaisy Medical? 大专占比最多占65.5%，其次是本科占23.6%. High education required at Kaisy Medical? 硕士占9.2%. Work experience required at Kaisy Medical? 1-3年占比最多占40.2%，其次是3-5年占27%. Where are the job locations at Kaisy Medical? 上海占比最多占24.7%，其次是北京占9.8%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
